Neurocrine Biosciences, Inc. (NBIX) — Fair Value Analysis
Base-case fair value (P50): $180.84 · Current price: $166.06 · Verdict: Fairly Valued
The Verdict on NBIX
Our Monte Carlo simulations indicate that NEUROCRINE BIOSCIENCES INC (NBIX) is currently Fairly Valued. With NBIX trading at $166.06, our median fair value (P50) stands at $180.84, suggesting an +8.9% potential. This robust assessment incorporates thousands of forward-looking scenarios, reflecting various market conditions and company performance trajectories. The proximity of the current market price to our calculated median fair value underscores the "Fairly Valued" verdict, implying that NBIX's intrinsic worth is largely reflected in its current equity price. While there is a slight +8.9% indicated, this falls within the range typical for a fairly priced asset based on our rigorous simulation methodology.
How NBIX stacks up against peers
Considering NBIX's operational and financial health, our analysis places it in the average quality tier relative to its sector. This classification reflects a balanced performance profile without significant outstanding strengths or critical weaknesses when benchmarked against industry peers. Such an average quality rating inherently influences our Monte Carlo-derived fair value, as it tempers extreme bullish or bearish outcomes. While the $166.06 suggests an +8.9% to our $180.84 target, this valuation thoughtfully factors in the company's established market position and its average fundamental strength within the industry, signaling a reasonable risk-reward profile.
What this means for investors
For investors, NBIX's current price of $166.06 being Fairly Valued against a median fair value of $180.84 implies limited immediate alpha potential from a pure valuation arbitrage perspective. The modest +8.9% indicates that the market is largely efficient in pricing this average quality enterprise. While our Monte Carlo model projects this median outcome, savvy investors understand that a full distribution of potential bear and bull cases provides a more complete risk-adjusted perspective. Discover the entire probability distribution for NBIX, including the P10 and P90 targets, by signing up for a free FairCurve account today and track its fair value as new fundamentals are released.
Frequently Asked Questions
Is NBIX overvalued or undervalued right now?
Based on our Monte Carlo simulations, NBIX is assessed as Fairly Valued. With a current price of $166.06 and a median fair value (P50) of $180.84, the market price closely aligns with its intrinsic worth.
What is the bear case and bull case for NBIX?
The full Monte Carlo distribution, including specific bear (P10) and bull (P90) target prices, plus the probability of upside, is exclusively available to FairCurve account holders. Sign up for free to access these detailed scenarios.
How does FairCurve calculate NBIX's fair value?
FairCurve calculates NBIX's fair value using advanced Monte Carlo simulations that model thousands of forward-looking scenarios for the company's financials. This robust approach provides a probabilistic range for intrinsic value.
How can I track NBIX's fair value as it changes?
You can add NBIX to your free FairCurve watchlist to receive daily fair-value updates. The system automatically re-values the stock instantly when new earnings or significant fundamental data are released.